Literature DB >> 8286741

Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma.

R J Kreitman1, P Bailon, V K Chaudhary, D J FitzGerald, I Pastan.   

Abstract

Anti-Tac(Fv)-PE40 is a recombinant single-chain immunotoxin composed of the variable domains of the monoclonal antibody anti-Tac, which binds to the p55 subunit of the interleukin-2 receptor (IL-2R), and a truncated form of Pseudomonas exotoxin (PE), which does not bind to the PE receptor (Chaudhary et al, Nature 339:394, 1989). Whereas its cytotoxic activity toward autoimmune and malignant target cells has been established, its efficacy in vivo remains unknown. To establish an animal model, we produced ATAC-4 cells by transfecting the gene encoding the low-affinity IL-2R (p55) into A431 epidermoid carcinoma cells. ATAC-4 cells contained low-affinity IL-2Rs (2 x 10(5)/cell) and formed tumors in nude mice. In tissue culture, protein synthesis in ATAC-4 cells was inhibited 50% (IC50) at 0.06 ng/mL (0.9 pmol/L) of anti-Tac(Fv)-PE40. IC50s for the derivatives anti-Tac(Fv)-PE38, which is missing PE amino acids 365-380, and anti-Tac(Fv)-PE38KDEL, which contains the same deletion plus the KDEL carboxyl terminus, were 0.04 and 0.025 ng/mL, respectively. All the agents produced complete tumor regressions in ATAC-4 tumor-bearing mice and anti-Tac(Fv)-PE38KDEL had significant antitumor activity at 1% of the LD50. The dose limiting toxicity of anti-Tac(Fv)-PE38KDEL was from hemorrhagic liver necrosis, which was observed at approximately 55% of the LD50.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8286741

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  29 in total

1.  Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.

Authors:  Ronit Mazor; Gilad Kaplan; Dong Park; Youjin Jang; Fred Lee; Robert Kreitman; Ira Pastan
Journal:  Cell Immunol       Date:  2017-01-05       Impact factor: 4.868

2.  Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.

Authors:  Rajat Singh; Yujian Zhang; Ira Pastan; Robert J Kreitman
Journal:  Clin Cancer Res       Date:  2011-11-08       Impact factor: 12.531

Review 3.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

4.  Renal excretion of recombinant immunotoxins containing pseudomonas exotoxin.

Authors:  Roberta Traini; Robert J Kreitman
Journal:  Bioconjug Chem       Date:  2011-03-16       Impact factor: 4.774

5.  In vitro evaluation of Pyrularia thionin-anti-CD5 immunotoxin.

Authors:  S E Gasanov; E D Rael; N E Gasanov; L P Vernon
Journal:  Cancer Immunol Immunother       Date:  1995-08       Impact factor: 6.968

6.  Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model.

Authors:  I H Pastan; G E Archer; R E McLendon; H S Friedman; H E Fuchs; Q C Wang; L H Pai; J Herndon; D D Bigner
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

7.  Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.

Authors:  Peter Attia; Daniel J Powell; Ajay V Maker; Robert J Kreitman; Ira Pastan; Steven A Rosenberg
Journal:  J Immunother       Date:  2006 Mar-Apr       Impact factor: 4.456

8.  Megalin contributes to the early injury of proximal tubule cells during nonselective proteinuria.

Authors:  Yaeko Motoyoshi; Taiji Matsusaka; Akihiko Saito; Ira Pastan; Thomas E Willnow; Shuki Mizutani; Iekuni Ichikawa
Journal:  Kidney Int       Date:  2008-09-03       Impact factor: 10.612

Review 9.  Antibody-based therapy of leukaemia.

Authors:  John C Morris; Thomas A Waldmann
Journal:  Expert Rev Mol Med       Date:  2009-09-30       Impact factor: 5.600

10.  Pseudomonas exotoxin antisense RNA selectively kills hepatitis B virus infected cells.

Authors:  Peter Hafkemeyer; Ulrich Brinkmann; Elizabeth Brinkmann; Ira Pastan; Hubert-E Blum; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.